Biochemical Pharmacology volume 77, issue 11, P1694-1701 2009 DOI: 10.1016/j.bcp.2009.03.004 View full text
Seung Hyun Kim, Jin Cheol Yoo, Tae Sung Kim

Abstract: A major goal in the treatment of acute myeloid leukemia (AML) is to achieve terminal differentiation and prevent drug resistance and side effects. Combined treatment with low doses of ATRA or 1,25-(OH)(2)D(3) that do not induce toxicity with another drug is one useful strategy for the treatment of AML. Actinomycetes are the well known sources of antibiotics and bioactive molecules. Previously, we isolated nargenicin from the culture broth of an actinomycete isolate, Nocardia sp. CS682. In this study, we evalua…

expand abstract